Data From WATER, WATER II and Single-Center Studies of PROCEPT BioRobotics Aquablation Therapy Will Be Revealed at the AUA

Two pivotal studies and one all-comers commercial series featuring PROCEPT® BioRobotics  Aquablation® therapy for the treatment of benign prostatic hyperplasia (BPH) will be presented at the American Urological Association (AUA) Annual Meeting at McCormick Place in Chicago, May 3 – 6, 2019. Aquablation therapy, delivered by the AquaBeam® Robotic System, is the only FDA cleared, autonomous robot for surgery.

PD10-12 “WATER II: Aquablation Therapy for Benign Prostatic Hyperplasia in Men with Large Prostates (80-150 mL): One-Year Safety and Efficacy Results”
May 3, 11:20 – 11:30 a.m.
One-year data from the WATER II Study (Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue), evaluating the safety and efficacy of Aquablation therapy in 101 men with large prostates 80 to 150 milliliters (mL) in size, will be presented by Naeem Bhojani, M.D., associate professor at the Université de Montréal, Montréal, Canada. The podium session PD10-12, titled “WATER II: Aquablation Therapy for Benign Prostatic Hyperplasia in Men with Large Prostates (80-150 mL): One-Year Safety and Efficacy Results,” follows the release of WATER II six-month data at the European Association of Urology Annual (EAU) Congress in March, which determined that Aquablation therapy is a safe surgical alternative for treating men with large prostates, where surgical options are limited.

MP45-11 “The WATER Study Clinical Results – Results at Two Years and Urodynamic Findings” May 4, 3:30 – 5:30 p.m.
Two-year follow-up data from the WATER Study, which compared the safety and efficacy of Aquablation therapy to the most common BPH surgical method, transurethral resection of the prostate (TURP), in 181 men with prostates between 30 and 80 mL in size, will be presented by Peter Gilling, M.D., co-principal investigator and professor of surgery at the University of Auckland, Bay of Plenty Clinical School Tauranga, New Zealand. The moderated poster MP45-11 titled, “The WATER Study Clinical Results – Results at Two Years and Urodynamic Findings,” will build on WATER Study one-year data featured at AUA 2018, which demonstrated similar durable outcomes at one year compared to TURP, a low retreatment rate and symptom improvement scores comparable to other resective techniques. Dr. Gilling recently received two awards at the USANZ annual conference related to this data set.

MP45-10 “Real-life Data From 180 Consecutive Patients Undergoing Aquablation of the Prostate” May 4, 3:30 – 5:30 p.m.
A third study, “Real-life Data From 180 Consecutive Patients Undergoing Aquablation of the Prostate,” will be presented by Prof. Thorsten Bach, chief physician in urology at Asklepios Hospital Harburg in Hamburg, Germany. The moderated poster MP45-10 will highlight single-center results of a consecutive, 180-patient cohort treated with Aquablation therapy between September 2017 and June 2018.

“These clinical presentations validate the durability, superior safety and gold standard-like effectiveness of Aquablation therapy in a broad range of prostates along with a large data set of real-world experience. We are thrilled to present this robust set of clinical data at AUA in Chicago,” said Nikolai Aljuri, Ph.D., PROCEPT BioRobotics, president and chief executive officer. “BPH is a condition that affects millions of men worldwide, and yet relatively few patients elect to treat their BPH with surgery due to potential complications. With Aquablation therapy, we offer patients a heat-free, minimally invasive and robotically controlled treatment option that helps alleviate their concerns and provides safe and effective symptom relief.”

For more information about Aquablation therapy, visit PROCEPT BioRobotics at AUA Booth #4027 at McCormick Place.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc.

WE WELCOME YOUR VIEWS

Please enter your comment!
Please enter your name here